Chemoradiotherapy showed no clear difference in overall survival compared with chemoradiotherapy plus surgery (high certainty).
Chemoradiotherapy probably leads to lower freedom from locoregional relapse compared with chemoradiotherapy plus surgery (moderate certainty).
Chemoradiotherapy may leads to higher treatment‐related mortality compared with chemoradiotherapy plus surgery (low certainty).
Chemoradiotherapy may leads to lower use of salvage procedures for dysphagia compared with chemoradiotherapy plus surgery (low certainty).
Concomitant (concurrent) chemoradiotherapy led to lower locoregional control, concurrent chemoradiotherapy (platinum +… compared with radiotherapy alone (non-resectable tumours); GRADE not reported.
Concomitant (concurrent) chemoradiotherapy led to lower disease-free survival, concurrent chemoradiotherapy vs radiotherapy… compared with radiotherapy alone (non-resectable tumours); GRADE not reported.
Concomitant (concurrent) chemoradiotherapy probably leads to lower overall survival, concurrent chemoradiotherapy vs radiotherapy alone… compared with radiotherapy alone (non-resectable tumours) (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether chemoradiotherapy changes recurrence compared with radical surgery (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether extended‐field chemoradiotherapy changes overall survival compared with pelvic chemoradiotherapy (very low certainty).
It is very uncertain whether extended‐field chemoradiotherapy changes para‐aortic lymph node recurrence compared with pelvic chemoradiotherapy (very low certainty).
It is very uncertain whether extended‐field chemoradiotherapy changes progression‐free survival compared with pelvic chemoradiotherapy (very low certainty).
It is very uncertain whether extended‐field chemoradiotherapy changes acute adverse events compared with pelvic chemoradiotherapy (very low certainty).
It is very uncertain whether extended‐field chemoradiotherapy changes late adverse events compared with pelvic chemoradiotherapy (very low certainty).
It is very uncertain whether hysterectomy (simple or radical) with chemoradiotherapy changes overall survival Median compared with chemoradiotherapy alone (very low certainty).
It is very uncertain whether hysterectomy (simple or radical) with chemoradiotherapy changes progression or event‐free survival Median compared with chemoradiotherapy alone (very low certainty).
The review found no eligible studies for this question.